deamidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
ANP modulates innate immunity by raising defence against extracellular microbes and inhibiting the release of pro-inflammatory markers and expression of adhesion molecules. There is evidence of cytoprotective effects of ANP in myocardial, vascular smooth, endothelial, hepatocytes and tumour cells.
=== Pregnancy and breastfeeding === Prolonged use of hydrocodone/paracetamol during pregnancy can result in neonatal opioid withdrawal syndrome. Hydrocodone/paracetamol passes into breast milk and may harm the baby.
Onyx Pharmaceuticals, Inc. was a pharmaceutical company headquartered in South San Francisco, California that developed and marketed cancer treatment medications. It was founded and incorporated with the California Secretary of State in February 1992 by venture capitalist Kevin J. Kinsella and Frank McCormick, Ph.D., FRS, D.Sc. (Hon.), a renowned British-American biochemist. McCormick served as the chief scientific officer until 1996, while Kinsella chaired the company's board of directors. On March 26, 1996, Onyx withdrew its corporate registration with the California Secretary of State and reincorporated in the state of Delaware in advance of successfully taking the company public on the NASDAQ exchange using National Market symbol ONXX on May 9, 1996. In 2009, the company acquired private biotechnology company Proteolix for US$276 million in cash plus additional milestone payments. In January 2012, the company was named "the top biotechnology takeover target in 2012" in an industry survey conducted by the ISI Group. Onyx president and CEO N. Anthony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patients. However, by the end of August 2013, Amgen announced that it was acquiring Onyx in an agreed US$10.4 billion deal.
An increase in hand washing compliance by hospital staff results in decreased rates of resistant organisms. Water supply and sanitation infrastructure in health facilities offer opportunities for combatting AMR, and investment should be increased. There is much room for improvement: WHO and UNICEF estimated in 2015 that 38% of health facilities did not have a source of water, nearly 19% had no toilets and 35% had no water and soap or alcohol-based hand rub for handwashing.
==== Acne vulgaris ==== As of 2012, evidence for light therapy and lasers in the treatment of acne vulgaris was not sufficient to recommend them. There is moderate evidence for the efficacy of blue and blue-red light therapies in treating mild acne, but most studies are of low quality. While light therapy appears to provide short-term benefit, there is a lack of long-term outcome data in those with severe acne.
Sources: en.wikipedia.org
On December 31, 2018, Tim Hortons had 4,846 restaurants in 14 countries, including 3,802 in Canada, 807 in the United States, 60 in Mexico, 29 in the Middle East, and 25 in the UK. As of August 2024, Tim Hortons has 5,702 restaurants.
=== Social Security === On March 18, 2025, the Social Security Administration announced they would be implementing tighter identity requirements starting March 31, with this date pushed forward to April 14. The new policy requires takes away the telephone option and requires individuals to either apply online or appear in-person at a field office. Applications for SSDI, Medicare, or SSI are exempted from this in-person requirement, along with applicants subject to extreme situations "such as terminal cases or prisoner pre-release scenarios". This new policy comes at a time the Trump administration is closing some field offices and laying off some Social Security staff. In late March, Wired reported that DOGE was putting together a team to migrate the Social Security base code from COBOL to a more modern programming language, with the goal of achieving this in a matter of months, whereas most experts say it should take several years to do and test this safely. It was reported in mid-April that the Trump administration had placed on the "Death Master File", renamed the "Ineligible Master File", more than 6,000 persons who are legal immigrants whom officials claim are either on a terrorism watch list or have an FBI criminal record. The White House, however, did not provide evidence for this claim. Social Security will "clawback" money from a disabled or retired person's monthly payments in cases in which overpayments are discovered.
== Complications == Visual phenomenon: Large epithelial plugs may cause more scattering of light, leading to the appearance of visual phenomena such as flares and starbursts – especially in situations such as night driving, where the stark light of car headlights abounds. These dark conditions cause the pupil to dilate, maximizing the amount of scattered light that enters the eye. In cases where large epithelial plugs lead to such aggravating symptoms, patients may seek further surgical treatment to alleviate the symptoms. Progressive hyperopia (farsightedness): RK enjoyed great popularity during the 1980s, and was one of the most studied refractive surgical procedures. Its 10-year data was published as the PERK (Prospective Evaluation of Radial Keratotomy) study, which proved the onset of progressive hyperopia – often found a decade after the original surgery – is due to continued flattening of the central cornea. Infectious keratitis: There is a risk of corneal infection after RK. Approximately half of infections occur within 2 weeks of surgery, but delayed infection do occur up to a year after surgery. Staphylococcus aureus was the most commonly identified bacteria for rapid onset and Pseudomonas aeruginosa was the most common identified bacteria for delayed onset. Refractive changes at high altitude: Changes in refractive power of post RK corneas at high altitude has been well documented. There is a significant increase in the cycloplegic refraction as well as corneal thickness measurements in RK corneas exposed to high altitude.
The evidence is circumstantial, and though it seems to implicate Mundt, Leamas repeatedly rejects that conclusion, claiming that an important East German official could not have been a British agent without his knowledge. However, Fiedler is able to independently confirm Leamas' information and comes to the conclusion that Mundt, his supervisor, has indeed been a secret asset of British intelligence for many years. Mundt himself unexpectedly arrives at the compound and has both Leamas and Fiedler arrested for plotting against him. Once Fiedler explains his findings to his superiors, the tables are turned and Mundt is arrested. A secret tribunal is convened to try Mundt for espionage, with Leamas compelled to testify. Fiedler presents a strong case for Mundt being a paid double agent. However, Mundt's attorney uncovers several discrepancies in Leamas' transformation into an informant, suggesting that Leamas is a faux defector. Leamas' credibility collapses when Nan, who has been brought to East Germany for what she thought was a cultural exchange visit, is forced to testify at the tribunal and unwittingly reveals that she has been receiving payments from a British intelligence officer as Leamas had arranged. Faced with this testimony, Leamas reluctantly admits that he is indeed a British agent. Mundt is vindicated, and Fiedler is arrested as a complicit dupe. Leamas initially believes he has failed in his mission and fears severe retribution from Mundt.
The name Generation Z is a reference to the fact that it follows Generation Y (Millennials). Other proposed names for the generation include iGeneration, Homeland Generation, Net Gen, Digital Natives, Neo-Digital Natives, Pluralist Generation, Centennials, and Post-Millennials. The term Internet Generation reflect that the generation is the first to have been born after the mass-adoption of the Internet. In the U.S., the term Generation Z is overwhelmingly the most popular. Zoomer is an informal term often used in an ironic, humorous, or ridiculing tone. It combines the term boomer, referring to baby boomers, with the "Z" from Generation Z. Prior to this, Zoomer was used in the 2000s to describe particularly active baby boomers. Zoomer in its current incarnation skyrocketed in popularity in 2018, when it was used in an Internet meme ridiculing Gen Z adolescents. Merriam-Webster's records suggest the use of the term zoomer in the sense of Generation Z dates back at least as far as 2016. It was added to the dictionary in 2021. In January 2019, Pew Research Center defined "Post-Millennials" as people born from 1997 onward, choosing this date for "different formative experiences" for the purposes of demographic analysis. Common generational experiences include technological developments and socioeconomic trends, including the widespread availability of wireless internet access and high-bandwidth cellular service, and key world events, such as growing up in a world after the September 11th terrorist attacks.
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.